[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484183":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":27,"locations":36,"responsibleParty":52,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Vanderbilt University Medical Center","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Idiopathic or Heritable Pulmonary Arterial Hypertension",null,"Patients diagnosed with pulmonary arterial hypertension, either idiopathic or heritable, defined according to standard criteria.",{"label":13,"type":10,"description":14,"interventionNames":10},"Unaffected Mutation Carriers","Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo.",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy Controls","Healthy individuals without cardiopulmonary disease",[19,23,25],{"name":20,"affiliation":21,"role":22},"Evan Brittain, MD","Vanderbilt Medical Center","PRINCIPAL_INVESTIGATOR",{"name":24,"affiliation":21,"role":22},"Anna Hemnes, MD",{"name":26,"affiliation":21,"role":22},"Eric Austin, MD",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Kelly Burke, RN","CONTACT","(615) 343-4682","kelly.burke@vumc.org",{"name":34,"role":30,"phone":31,"phoneExt":10,"email":35},"Alisha Lindsey, RT","alisha.lindsey@vumc.org",[37],{"facility":5,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Nashville","Tennessee","37232","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-86.78444,36.16589,{"lat":48,"lon":47},[51],{"name":29,"role":30,"phone":10,"phoneExt":10,"email":32},{"type":22,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Anna Hemnes","MD","100484183","risk-and-resilience-in-pulmonary-arterial-hypertension-and-genetically-susceptible-individuals-100484183",false,"NCT05584722","Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals","RARE-PAH","Inclusion Criteria:\n\n* Children and Adults, aged 15 - 80\n* Diagnosed with idiopathic or heritable, pulmonary arterial hypertension (PAH), defined according to standard criteria\n* Unaffected Mutation Carriers: Healthy participants with a known BMPR2 gene mutation and normal pulmonary pressure and RV function on echo\n* Healthy Controls: Healthy individuals without cardiopulmonary disease.\n* WHO functional class I-III\n* Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.\n\nExclusion Criteria:\n\n* Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane\u002Fwalker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.\n* Pregnancy\n* Diagnosis of PAH etiology other than idiopathic, heritable\n* Functional class IV heart failure\n* Requirement of \\> 2 diuretic adjustment in the prior three months.","ALL","15 Years","80 Years",{"count":66,"type":67},150,"ESTIMATED","OBSERVATIONAL","Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets.\n\nFunding Source - FDA OOPD",[71,72,73,74],"Idiopathic Pulmonary Arterial Hypertension","Heritable Pulmonary Arterial Hypertension","Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo","Healthy Individuals With no Cardiopulmonary Disease",[76],"pulmonary hypertension","2026-03-09",{"date":79,"type":80},"2026-03-10","ACTUAL",{"date":82,"type":80},"2022-11-01",{"date":84,"type":67},"2026-08-31",{"name":5,"class":6},1]